Parc d’Innovation, Illkirch, France, September 2, 2009 – Transgene (Euronext Paris: FR0005175080) announces results for the first half of 2009.
Highlights of the first half of 2009 include:
• TG4010 (MVA-MUC1-IL2): targeted immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Long-term data presented at AACR and ASCO during the first half of 2009 confirm positive efficacy results on a major sub-population of patients. In June 2009, the FDA gave its green light to proceed to phase III trial on this sub-population of patients.
• TG4040 (MVA-HCV): active immunotherapy for the treatment of chronic hepatitis C. Focus on controlled phase II trial preparation following presentation of most recent data at EASL.
• Inauguration of new R&D facility and Transgene’s headquarters in the Parc d’Innovation d’Illkirch, next to Strasbourg, inaugurated on June 24, 2009.
• Cash burn of €5.1m for the first half of 2009 following accelerated refund of research tax credits and receipt of ADNA grants.
• Cash position of €81.6m as of June 30, 2009.
“This first half of 2009 was very positive for Transgene. We have made significant progress across our clinical pipeline and are now progressing towards the next phases as planned. Discussions in view of a development partnership for TG4010 are on-going. Our cash burn which benefited from significant cash receipts in the first half should reach approximately € 22m for the whole year 2009, excluding potential partnership revenues” Philippe Archinard, Chief Executive Officer of Transgene, commented.
Disclaimer
The information in this email and any attachments may contain proprietary and confidential information that is intended for the addressee(s) only. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, retention or use of the contents of this information is prohibited. When addressed to our clients or vendors, any information contained in this e-mail or any attachments is subject to the terms and conditions in any governing contract. If you have received this e-mail in error, please immediately contact the sender and delete the e-mail.
